{"title":"甘精胰岛素比艾塞那肽更适合预防非肥胖2型糖尿病NAFLD患者的肌肉损失。","authors":"Lin Liu, Ruwen Wang, Jian Gao, Jianhua Yan, Jingtian Zhang, Zhitian Zhang, Jiaojiao Liu, Huandong Lin, Shengxiang Rao, Xiuzhong Yao, Weiyun Wu, Hua Bian, Xiangyu Wang, Shanshan Guo, Xin Gao, Hongmei Yan","doi":"10.1055/a-2145-1004","DOIUrl":null,"url":null,"abstract":"<p><strong>Aim: </strong>This study investigated the effects of insulin glargine and exenatide on the muscle mass of patients with newly diagnosed type 2 diabetes (T2DM) and nonalcoholic fatty liver disease (NAFLD).</p><p><strong>Methods: </strong>We performed a post-hoc analysis of our previously study, a 24-week randomized controlled multicenter clinical trial (ClinicalTrials.gov, NCT02303730). Seventy-six patients were randomly assigned 1:1 to receive insulin glargine or exenatide treatment. The changes in psoas muscle area (PMA) (mm<sup>2</sup>) were obtained with the cross-sectional Dixonfat magnetic resonance images at the fourth lumber vertebra.</p><p><strong>Results: </strong>There were no significant differences in age, BMI, gender, and PMA in insulin glargine and exenatide groups at baseline. After treatment, PMA tended to increase by 13.13 (-215.52, 280.80) mm<sup>2</sup> in the insulin glargine group and decrease by 149.09 (322.90-56.39) mm<sup>2</sup> in the exenatide group (both <i>p></i>0.05). Subgroup analysis showed a 560.64 (77.88, 1043.40) (mm<sup>2</sup>) increase of PMA in the insulin group relative to the Exenatide group in patients with BMI<28 kg/m<sup>2</sup> (<i>p</i>0.031) after adjusting for gender, age, and research center. Interaction analysis showed an interaction between BMI and treatment (<i>p</i>0.009). However, no interaction was observed among subgroups with a BMI≥28 kg/m<sup>2</sup> or with different genders and ages.</p><p><strong>Conclusion: </strong>Compared to exenatide, insulin glargine can relativity increase PMA in patients with T2DM having BMI<28 kg/m<sup>2</sup> and NAFLD.</p>","PeriodicalId":12241,"journal":{"name":"Experimental and Clinical Endocrinology & Diabetes","volume":null,"pages":null},"PeriodicalIF":1.6000,"publicationDate":"2023-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10645484/pdf/","citationCount":"0","resultStr":"{\"title\":\"Insulin Glargine is More Suitable Than Exenatide in Preventing Muscle Loss in Non-Obese Type 2 Diabetic Patients with NAFLD.\",\"authors\":\"Lin Liu, Ruwen Wang, Jian Gao, Jianhua Yan, Jingtian Zhang, Zhitian Zhang, Jiaojiao Liu, Huandong Lin, Shengxiang Rao, Xiuzhong Yao, Weiyun Wu, Hua Bian, Xiangyu Wang, Shanshan Guo, Xin Gao, Hongmei Yan\",\"doi\":\"10.1055/a-2145-1004\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Aim: </strong>This study investigated the effects of insulin glargine and exenatide on the muscle mass of patients with newly diagnosed type 2 diabetes (T2DM) and nonalcoholic fatty liver disease (NAFLD).</p><p><strong>Methods: </strong>We performed a post-hoc analysis of our previously study, a 24-week randomized controlled multicenter clinical trial (ClinicalTrials.gov, NCT02303730). Seventy-six patients were randomly assigned 1:1 to receive insulin glargine or exenatide treatment. The changes in psoas muscle area (PMA) (mm<sup>2</sup>) were obtained with the cross-sectional Dixonfat magnetic resonance images at the fourth lumber vertebra.</p><p><strong>Results: </strong>There were no significant differences in age, BMI, gender, and PMA in insulin glargine and exenatide groups at baseline. After treatment, PMA tended to increase by 13.13 (-215.52, 280.80) mm<sup>2</sup> in the insulin glargine group and decrease by 149.09 (322.90-56.39) mm<sup>2</sup> in the exenatide group (both <i>p></i>0.05). Subgroup analysis showed a 560.64 (77.88, 1043.40) (mm<sup>2</sup>) increase of PMA in the insulin group relative to the Exenatide group in patients with BMI<28 kg/m<sup>2</sup> (<i>p</i>0.031) after adjusting for gender, age, and research center. Interaction analysis showed an interaction between BMI and treatment (<i>p</i>0.009). However, no interaction was observed among subgroups with a BMI≥28 kg/m<sup>2</sup> or with different genders and ages.</p><p><strong>Conclusion: </strong>Compared to exenatide, insulin glargine can relativity increase PMA in patients with T2DM having BMI<28 kg/m<sup>2</sup> and NAFLD.</p>\",\"PeriodicalId\":12241,\"journal\":{\"name\":\"Experimental and Clinical Endocrinology & Diabetes\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":1.6000,\"publicationDate\":\"2023-11-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10645484/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Experimental and Clinical Endocrinology & Diabetes\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1055/a-2145-1004\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2023/7/31 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q4\",\"JCRName\":\"ENDOCRINOLOGY & METABOLISM\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Experimental and Clinical Endocrinology & Diabetes","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1055/a-2145-1004","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/7/31 0:00:00","PubModel":"Epub","JCR":"Q4","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}
Insulin Glargine is More Suitable Than Exenatide in Preventing Muscle Loss in Non-Obese Type 2 Diabetic Patients with NAFLD.
Aim: This study investigated the effects of insulin glargine and exenatide on the muscle mass of patients with newly diagnosed type 2 diabetes (T2DM) and nonalcoholic fatty liver disease (NAFLD).
Methods: We performed a post-hoc analysis of our previously study, a 24-week randomized controlled multicenter clinical trial (ClinicalTrials.gov, NCT02303730). Seventy-six patients were randomly assigned 1:1 to receive insulin glargine or exenatide treatment. The changes in psoas muscle area (PMA) (mm2) were obtained with the cross-sectional Dixonfat magnetic resonance images at the fourth lumber vertebra.
Results: There were no significant differences in age, BMI, gender, and PMA in insulin glargine and exenatide groups at baseline. After treatment, PMA tended to increase by 13.13 (-215.52, 280.80) mm2 in the insulin glargine group and decrease by 149.09 (322.90-56.39) mm2 in the exenatide group (both p>0.05). Subgroup analysis showed a 560.64 (77.88, 1043.40) (mm2) increase of PMA in the insulin group relative to the Exenatide group in patients with BMI<28 kg/m2 (p0.031) after adjusting for gender, age, and research center. Interaction analysis showed an interaction between BMI and treatment (p0.009). However, no interaction was observed among subgroups with a BMI≥28 kg/m2 or with different genders and ages.
Conclusion: Compared to exenatide, insulin glargine can relativity increase PMA in patients with T2DM having BMI<28 kg/m2 and NAFLD.
期刊介绍：
Publishing outstanding articles from all fields of endocrinology and diabetology, from molecular biology to clinical research, this journal is a brilliant resource. Since being published in English in 1983, the popularity of this journal has grown steadily, reflecting the importance of this publication within its field.
Original contributions and short communications appear in each issue along with reviews addressing current topics. In addition, supplementary issues are published each year presenting abstracts or proceedings of national and international scientific meetings.
The journal was initially published in German and is still the oldest endocrinological periodical in the German-language market!
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
